Noninfringement Finding In Biologics Dispute Affirmed By Panel

Mealey's (May 9, 2019, 12:21 PM EDT) -- WASHINGTON, D.C. — A California federal judge’s determination that a Sandoz Inc. filgrastim biosimilar and proposed pegfilgrastim biosimilar product do not infringe an Amgen patent relating to Neupogen and Neulasta was not erroneous, the Federal Circuit U.S. Court of Appeals ruled May 8 (Amgen Inc., et al., v. Sandoz Inc., No. 18-1551, Fed. Cir., 2019 U.S. App. LEXIS 13738)....